Clinical Nutrition

GLUTAPAK® R

  • Contains Glutamine that Nourishes Gastrointestinal Cells and Helps Repair Intestinal Damage Caused by Disease, Infection and Metabolic Stress
  • Contains Lactobacillus Reuteri, a Superior Probiotic that Effectively Colonizes the Gastrointestinal Tract and Fights off Pathogens that Cause Diarrhea and Other Gastrointestinal Disorders
  • Clinically Proven to Reduce Gastrointestinal Discomfort and Improve Bowel Function
  • Clinically Proven to Reduce Diarrhea

Available Options

* Sale Unit:
Qty:   $24.59  
GLUTAPAK® R

Combination of Glutamine and L. Reuteri

 

Glutapak® R provides 10 g of glutamine and 100 million colony-forming units (CFU) of the superior probiotic, Lactobacillus reuteri.  Glutamine nourishes the intestinal cells and helps repair damage to the intestinal walls due to injury or disease, improving digestion, absorption, and the patient's nutritional status. L. reuteri restores the intestinal flora and inhibits the growth of pathogens that cause diarrhea and other intestinal problems. Protected by corresponding patents 5,849,289 and 7,374,924 and other issued and pending patents.

 

Glutamine + Lactobacillus reuteri Combination

Glutamine

  • Conditionally essential amino acid that nourishes the cells of the gastrointestinal tract
  • Helps repair intestinal damage caused by diseases, infections and metabolic stress
  • Clinically proven to reduce gastrointestinal discomfort and improve bowel function

Lactobacillus Reuteri

  • A superior probiotic that effectively colonizes the gastrointestinal tract
  • Fights off pathogens that cause diarrhea and other gastrointestinal disorders
  • Clinically proven to reduce diarrhea and restore intestinal balance

USE UNDER MEDICAL SUPERVISION

 

PRESENTATION: POWDER

Catalog Number Units per Case Size
70022 50 single sachets 15 g
73122 16 three-packs 3  of 15 g
73022 1 three-packs 3  of 15 g
*This product cannot be sold or distributed in the State of Vermont.
 

NUTRITIONAL INFORMATION
Nutrients per serving (4.5 g)


Calories (kcal) 60
Energy (kJ) 251
Protein (as L-glutamine)(g) 10
Carbohydrates (g) 5
Sugar (g) 0
Fat (g) 0
L. reuteri 100 million CFU

Ingredients: Lactobacillus reuteri, L-glutamine, maltodextrin

Caloric Distribution
Protein (% kcal) 66.7
Carbohydrate (% kcal) 33.3
Fat (% kcal) 0
Gluten free Yes
Lactose free Yes

*When prepared in 60 mL of water per instructions

 

DIRECTIONS OF USE

For oral use: Mix Glutapak® R with 60-120 mL (2-4 oz) of beverage or food that is at a tolerable temperature range of 10°C - 45°C (50°F - 113°F) and consume immediately.

For tube feeding: Mix Glutapak® R with 60-120 mL (2-4 oz) of water and administer through a feeding tube immediately. Flush the feeding tube before and after administration.

Glutapak® R should not be mixed at extremely hot (above 45°C) or extremely cold (below 10°C) temperatures because this may affect the Lactobacillus reuteri.

Glutapak® R should not be mixed with enteral formulas administered through a feeding tube.

 

PRECAUTIONS

GLUTAPAK® R IS NOT A COMPLETE DIET
GLUTAPAK® R SHOULD NOT BE HEATED, FROZEN, OR STERILIZED
NOT FOR PARENTERAL USE
USE UNDER MEDICAL SUPERVISION

FREQUENTLY ASKED QUESTIONS

 

We currently have no frequently asked questions for this product. If you have any questions please click here.

  • Aguilar-Nascimento J, Caporossi C, Boyd D, de Arruda I, Moreno K, Moreno W. Oral glutamine in addition to parenteral nutrition improves mortality and the healing of high-output intestinal fistulas. Nutri Hosp 2007;22:672-6.
  • Axelsson L, Chung TC, Dobrogosz WJ, Lindgren SE. Production of a broad-spectrum antimicrobial substance by Lactobacillus reuteri. Microb Ecol Health Dis 1989;2:131-136.
  • Bromhall CM, DiMarco N, Moreland K, Eastman A. A Retrospective Analysis of the Effect of an Enteral Glutamine & Probiotic Supplement on Diarrhea in the Surgical Intensive Care Unit Patient. Abstract N93. Presented at the American Society for Parenteral and Enteral Nutrition Clinical Nutrition Week, Vancouver, BC Canada, Jan 30-Feb 1, 2011.
  • Coeffier M, Hecketsweiler B, Hecketsweiler P, Dechelotte P. Effect of glutamine on water and sodium absorption in human jejunum at baseline and during PGE1-induced secretion. J Appl Physiol 2005;98:2163-68.
  • Houses I, Dobrogosz W. Validation of the probiotic concept: Lactobacillus reuteri confers Broad-Spectrum Protection against disease in humans and animals. Microb Ecol Health Dis 2000;12:247-285.
  • Imase K, Tanaka A, Tokunaga K, Sugano M, Ishida H, Takahashi S. Lactobacillus reuteri tablets suppress Helicobacter pylori infection-A double-blind randomized placebo-controlled. JJA Inf 2007;81:387-393.
  • Lionetti E, Miniello VL, Castellaneta SP, Master AM, de Canio A, Maurogiovanni G Ierardis E, Cavallo L, Francavilla R. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. Aliment Pharmacol Ther 2006;24:1461-1468.
  • McQuiggan M, Kozar R, Sailors RM, Ahn C, McKinley B, Moore F. Enteral glutamine during active shock resuscitation is safe and enhances tolerance of enteral feeding. JPEN 2008;32(1):28-35.
  • Moreno N, Barbella of Szarvas S, Moreno Veliz N, Castro de Kolster C. Utilidad del uso de un probiótico en niños desnutridos tratados con antibióticos. VITAE Biomedical Digital Academy. Number 25, Oct - Dec 2005. Link:https://tspace.library.utoronto.ca/bitstream/1807/9257/1/va05020.pdf
  • Mukai T, Asasaka T, Sato E. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol 2002;32:105-10.
  • Romeo MG, Betta P, Trovato L, Olivieri S. The role of probiotics in the prevention of bacterial infections and candida in neonatal intensive care. Prospective study with control groups. J Perinat Med 2006;34:A6.
  • Ruiz-Palacios G, Tuz F, Arteaga F, Guerrero ML, Dohnalek M, Hilty M. Tolerance and fecal colonization with Lactobacillus reuteri in children fed a beverage with a mixture of Lactobacillus spp. (Abstract) Pediatr Res 1996;39:184A.
  • Shornikova AV, Casas I, Isolauri E, Mykkänen, Salo E, Vesikari T. Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr Infect Dis J 1997;16:1103-1107.
  • Shornikova AV, Casas I, Isolauri E, Mykkänen, Vesikari T. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. Pediatr Gastro Nutr J 1997;24:399-404
  • Shornikova A, Casas R, Mykkänen H, et al. Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr Infect Dis J 1997;16:103-107.
  • Tae-Hun F, Eun-Young O, Young-Hoon K, Hyun-Scung L, Pil-Sang J, Dong-A K, Jin-Tack K, Byung-Churl L. The therapeutic effect of Lactobacillus reuteri in acute diarrhea in infants and toddlers. Korean J Pediatr 2005;48(9):986-990.
  • Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 2005;115:5-9.
  • Wolf BF, Garleb KA, Ataya DG, Casas IA. Safety and tolerance of Lactobacillus reuteri in healthy adult male subjects. Microb Ecol Health Dis 1995;8:41-50.
  • Wolf BW, Wheeler KB, Ataya DG, Garleb KA. Safety and tolerance of Lactobacillus reuteri supplementation to a population infected with the Human Immunodeficiency Virus. Food Chem Toxicol 1998;36:1085-1094.